{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:38Z","timestamp":1787020718610,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biogen Spain","award":["PO 17947"],"award-info":[{"award-number":["PO 17947"]}]},{"name":"Novartis spain","award":["Novartis spain"],"award-info":[{"award-number":["Novartis spain"]}]},{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","award":["Roche Espa\u00f1a"],"award-info":[{"award-number":["Roche Espa\u00f1a"]}],"id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FundAME","award":["FundAME"],"award-info":[{"award-number":["FundAME"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a need to expand the current scope of assessment tools usually applied to patients with Spinal Muscular Atrophy (SMA). This study aimed to assess the psychometric properties (reliability and discriminant validity) of a set of new patient-reported outcome measures (PROMs) called PROfuture, after analysing the performance of individual items of the questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients included in the Spanish SMA Patient-Reported Registry (RegistrAME) were invited to answer 10 questionnaires: Fatigability; Pain; Scoliosis and Contractures (S&amp;C); Feeding (F); Breathing and Voice (B&amp;V); Sleep and Rest (S&amp;R); Vulnerability; Infections and Hospitalisations (I&amp;H); Time spent in care (T); and Mobility and Independence (M&amp;I). The diagnosis date, type of SMA, functional classification, and comorbidities were also collected. A total of 160 patients of the 330 included in RegistrAME participated in the study: mean age (SD) 18 (16.6) years, 27.5% non-sitter, 46.88% sitter, and 25.63% walker, 20.0% type 1 SMA, 51.88% type 2, and 28.12% type 3. The frequency of symptoms varied from 43.5% of patients reporting some degree of Pain to 96.3% reporting some degree of Fatigability. The reliability assessed by Cronbach\u2019s alpha coefficient was &gt;\u20090.75 for all the PROs and &gt;\u20090.9 for S&amp;C, F, B&amp;V, T, and M&amp;I. Regarding content validity, scores were higher (worse health status) in type 1 SMA patients than in types 2 and 3, and were also higher for non-sitter patients than for sitter and walker patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ten questionnaires included in the PROfuture set were developed based on what people living with spinal muscular atrophy and their caregivers consider relevant. This preliminary study provides an initial basis to consider their potential usefulness in assessing aspects that matter to this population. The early findings are promising, however, further extensive psychometric evaluation is needed. PROfuture is a new set of patient-reported outcome measures, specifically designed by and for individuals living with spinal muscular atrophy and their caregivers. Future studies will help strengthen the evidence regarding its reliability and validity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03832-y","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T06:15:26Z","timestamp":1749017726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preliminary psychometric validation of patient-reported outcomes relevant to individuals with spinal muscular atrophy and their caregivers"],"prefix":"10.1186","volume":"20","author":[{"given":"Maria Grazia","family":"Cattinari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Ignacio","family":"Pascual-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menc\u00eda","family":"de Lemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julita","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"V\u00e1zquez-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"1","key":"3832_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","volume":"46","author":"JA Markowitz","year":"2012","unstructured":"Markowitz JA, Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 2012;46(1):1\u201312.","journal-title":"Pediatr Neurol"},{"key":"3832_CR2","doi-asserted-by":"crossref","unstructured":"Farrar MA, Kiernan MC. The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics. 2015;12(2):290\u2013302.","DOI":"10.1007\/s13311-014-0314-x"},{"issue":"4","key":"3832_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"issue":"1","key":"3832_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3832_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >\u200972,400 specimens. Eur J Hum Genetics: EJHG. 2012;20(1):27\u201332.","journal-title":"Eur J Hum Genetics: EJHG"},{"issue":"1","key":"3832_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40120-021-00307-7","volume":"11","author":"E Viscidi","year":"2022","unstructured":"Viscidi E, Juneja M, Wang J, Wang N, Li L, Farwell W, et al. Comparative All-Cause mortality among a large population of patients with spinal muscular atrophy versus matched controls. Neurol Therapy. 2022;11(1):449\u201357.","journal-title":"Neurol Therapy"},{"key":"3832_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","volume":"15","author":"Y Qian","year":"2015","unstructured":"Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217.","journal-title":"BMC Neurol"},{"issue":"3","key":"3832_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejpn.2019.03.004","volume":"23","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Edstr\u00f6m J, Sejersen T, Tulinius M, Lochm\u00fcller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: A systematic review. Eur J Pediatr Neurology: EJPN: Official J Eur Pediatr Neurol Soc. 2019;23(3):347\u201356.","journal-title":"Eur J Pediatr Neurology: EJPN: Official J Eur Pediatr Neurol Soc"},{"issue":"1","key":"3832_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13023-020-01498-2","volume":"15","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the cure SMA community update survey. Orphanet J Rare Dis. 2020;15(1):217.","journal-title":"Orphanet J Rare Dis"},{"key":"3832_CR10","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano E et al. The economic impact and Health-Related quality of life of spinal muscular atrophy. An analysis across Europe. Int J Environ Res Public Health. 2020;17(16).","DOI":"10.3390\/ijerph17165640"},{"issue":"3","key":"3832_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The children\u2019s hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disorders: NMD. 2010;20(3):155\u201361.","journal-title":"Neuromuscul Disorders: NMD"},{"issue":"2 Pt 1","key":"3832_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","volume":"135","author":"L Haataja","year":"1999","unstructured":"Haataja L, Mercuri E, Regev R, Cowan F, Rutherford M, Dubowitz V, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr. 1999;135(2 Pt 1):153\u201361.","journal-title":"J Pediatr"},{"issue":"9\u201310","key":"3832_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disorders: NMD. 2007;17(9\u201310):693\u20137.","journal-title":"Neuromuscul Disorders: NMD"},{"issue":"6","key":"3832_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374.","journal-title":"Muscle Nerve"},{"issue":"10","key":"3832_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","volume":"74","author":"J Montes","year":"2010","unstructured":"Montes J, McDermott MP, Martens WB, Dunaway S, Glanzman AM, Riley S, et al. Six-Minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74(10):833\u20138.","journal-title":"Neurology"},{"issue":"12","key":"3832_CR16","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1111\/ene.15542","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, et al. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2022;29(12):3666\u201375.","journal-title":"Eur J Neurol"},{"issue":"1","key":"3832_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17(1):68.","journal-title":"BMC Neurol"},{"issue":"13","key":"3832_CR18","doi-asserted-by":"publisher","first-page":"e1206","DOI":"10.1212\/WNL.0000000000006241","volume":"91","author":"P Mongiovi","year":"2018","unstructured":"Mongiovi P, Dilek N, Garland C, Hunter M, Kissel JT, Luebbe E, et al. Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA). Neurology. 2018;91(13):e1206\u201314.","journal-title":"Neurology"},{"key":"3832_CR19","doi-asserted-by":"crossref","unstructured":"De Lemus M, Cattinari MG, Pascual SI, Medina J, Garc\u00eda M, Magall\u00f3n A et al. Identification of the most relevant aspects of spinal muscular atrophy (SMA) with impact on the quality of life of SMA patients and their caregivers: the profuture project, a qualitative study. J Patient-Rep Outcomes. 24 de julio de 2024;8:78.","DOI":"10.1186\/s41687-024-00758-0"},{"issue":"1","key":"3832_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13023-024-03071-7","volume":"19","author":"MG Cattinari","year":"2024","unstructured":"Cattinari MG, de Lemus M, Tizzano E. RegistrAME: the Spanish self-reported patient registry of spinal muscular atrophy. Orphanet J Rare Dis. 2024;19(1):76.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3832_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.nmd.2020.02.019","volume":"30","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Messina S, Montes J, Muntoni F, Sansone VA. Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019. Neuromuscul Disorders: NMD. 2020;30(5):431\u20136.","journal-title":"Neuromuscul Disorders: NMD"},{"issue":"5","key":"3832_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","volume":"31","author":"N Gusset","year":"2021","unstructured":"Gusset N, Stalens C, Stumpe E, Klouvi L, Mejat A, Ouillade MC, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disorders: NMD. 2021;31(5):419\u201330.","journal-title":"Neuromuscul Disorders: NMD"},{"key":"3832_CR23","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Costa JF, Branas-Pampill\u00f3n M, Medina-Cantillo J, Povedano M, Pitarch-Castellano I, L\u00f3pez-Lobato M et al. Validation of a set of instruments to assess Patient- and Caregiver-Oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study. Neurol Therapy. 2022.","DOI":"10.1007\/s40120-022-00411-2"},{"key":"3832_CR24","doi-asserted-by":"publisher","first-page":"120059","DOI":"10.1016\/j.jns.2021.120059","volume":"432","author":"D Trundell","year":"2022","unstructured":"Trundell D, Skalicky A, Staunton H, Hareendran A, Le Scouiller S, Barrett L, et al. Development of the SMA independence scale-upper limb module (SMAIS-ULM): A novel scale for individuals with type 2 and non-ambulant type 3 SMA. J Neurol Sci. 2022;432:120059.","journal-title":"J Neurol Sci"},{"issue":"3","key":"3832_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pri.221","volume":"6","author":"B Steffensen","year":"2001","unstructured":"Steffensen B, Hyde S, Lyager S, Mattsson E. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiotherapy Res International: J Researchers Clin Phys Therapy. 2001;6(3):119\u201334.","journal-title":"Physiotherapy Res International: J Researchers Clin Phys Therapy"},{"issue":"6","key":"3832_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mus.27223","volume":"63","author":"CE Zizzi","year":"2021","unstructured":"Zizzi CE, Luebbe E, Mongiovi P, Hunter M, Dilek N, Garland C, et al. The spinal muscular atrophy health index: A novel outcome for measuring how a patient feels and functions. Muscle Nerve. 2021;63(6):837\u201344.","journal-title":"Muscle Nerve"},{"key":"3832_CR27","doi-asserted-by":"crossref","unstructured":"Domine MC, Cattinari MG, De Lemus M, Castellano IP, \u00d1ungo Garz\u00f3n NC, Sevilla-Matec\u00f3n T et al. Physical fatigue and perceived fatigability in adolescents and adults with spinal muscular atrophy: a pilot study. Neurol Perspect. 2022.","DOI":"10.1016\/j.neurop.2022.06.008"},{"issue":"2","key":"3832_CR28","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/WNL.0000000000007742","volume":"93","author":"CA Wijngaarde","year":"2019","unstructured":"Wijngaarde CA, Brink RC, de Kort FAS, Stam M, Otto LAM, Asselman FL, et al. Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology. 2019;93(2):e149\u201358.","journal-title":"Neurology"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03832-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03832-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03832-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:02:51Z","timestamp":1749060171000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03832-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3832"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03832-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the \u201cHospital Cl\u00ednico San Carlos\u201d of Madrid (21\/561-E). All participants provided their informed consent to participate in the registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MGC\n                      has received support from Roche for attendance at scientific congresses.\n                      SIPP\n                      has received honoraria for conferences, consultancies, and participation in clinical trials with Biogen, Roche and Novartis outside the submitted work.\n                      ML\n                      has offered advisory support to Roche in the development of risdiplam.\n                      JM\n                      has received honoraria for conferences, consultancies, and participation in clinical trials with Biogen, PTC, Roche, and Avexis outside the submitted work.\n                      MD\n                      has no conflict of interest to declare.\n                      PR\n                      was an employee of IQVIA who received an honorarium from Fundame in connection with the development of this manuscript.\n                      JFVC\n                      is funded by grants of the Instituto de Salud Carlos III (JR19\/00030, PI V\u00e1zquez) and received personal fees from Biogen and Roche outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}